Week Adjourned: 8.2.13 – Apple Store, Pfizer, Chester Career College

The week’s top class action lawsuits and settlements for the week ending August 2, 2013. Top lawsuits include Apple employees claiming wage and hour violations, Pfizer Rapamune Off Label marketing fines and Chester Career College settling consumer fraud charges.

.appleTop Class Action Lawsuits

Bad Apple! It seems Apple may be entering the ever-growing list of wage and hour offenders. This week, a class action lawsuit was filed against the tech giant, alleging that Apple store staff are not paid for the time they spend undergoing bag searches, as required by the company’s policy.

Apple has a policy of requiring its retail store employees to undergo two mandatory bag searches per day. Two former Apple store employees from New York and Los Angeles filed a complaint in San Francisco federal court on Thursday regarding this policy. They allege they had to stand in lines up to 30 minutes long every day for store managers to check their bags and ensure they weren’t smuggling home stolen goods. The Apple unpaid wages lawsuit claims that the cumulative time employees spend having these bag searches done totals dozens of hours of unpaid wages, roughly $1,500 per year.

“Apple has engaged and continues to engage in illegal and improper wage practices that have deprived Apple Hourly Employees throughout the United States of millions of dollars in wages and overtime compensation,” the complaint reads.

“These practices include requiring Apple Hourly Employees to wait in line and undergo two off-the-clock security bag searches and clearance checks when they leave for their meal breaks and after they have clocked out at the end of their shifts.”

 

According to the complaint, Apple’s retail stores employ some 42,400 people in 13 countries. The retail outlets generated net sales of $156.5 billion in 2012. Most hourly workers make between minimum wage and $18.75 per hour and work 40 hours per week.

Amanda Frlekin and Dean Pelle, the two former employees who filed the wage and hour lawsuit, worked as “specialists,” essentially an in-store customer support position. The Apple lawsuit describes the bag searches as “required but uncompensated security checks,” claiming that Apple violated the Fair Labor Standards Act (FLSA), and New York labor law, and California labor law.

Top Settlements

Off-label Drug Marketing Saga Continues—this week, it’s news that Pfizer will have to pony up $491 million to settle criminal and civil charges relating to its off-label marketing of Rapamune. The US Justice Department had claimed the drug company marketed the kidney-transplant drug for patients who received non-kidney organ transplants.

The Justice Department began its investigation over four years ago, and Pfizer inherited the probe when it bought Wyeth in 2009.

According to the Justice Department, Wyeth trained sales reps to push Rapamune for unapproved uses and offered bonuses to persuade them to flog the drug for patients it wasn’t cleared to treat. “This was a systemic, corporate effort to seek profit over safety,” U.S. Attorney Sanford Coats said in a statement. “Companies that ignore compliance with FDA regulations will face criminal prosecution and stiff penalties.”

Under the Pfizer Rapamune settlement agreement, Pfizer’s Wyeth division pleaded guilty to a criminal misbranding violation under the Food, Drug and Cosmetics Act. The deal includes a criminal fine of $157.58 million and asset forfeiture amounting to $76 million, or $233.5 million total. Civil payments to the government and states add another $257.4 million, for a total of $490.9 million. Okee dokee…

Looks like Chester Career College hit the Learning Curve on this one—at a cost of $5 million. That’s the settlement that was just approved ending a financial consumer fraud class action lawsuit pending against the college, formerly known as Richmond School of Health and Technology. The lawsuit alleged that the for-profit college practices predatory lending practices affecting thousands of students, primarily African American students, while offering sub-par education.

The back story—Chester Career College purportedly offers classes leading to careers in nursing, massage therapy and other medical-related fields, and specifically targeted inner city students with ads on hip-hop stations and other media aimed at their demographic. According to the lawsuit, the college enrolled “almost exclusively” students who qualified for federal financial aid, primarily in the form of student loans.

The Chester Career College settlement, approved by US District Judge John A. Gibney, will also see the school reimburse more than 4,000 students and for attorneys’ fees and requires Chester Career College to institute changes that will provide prospective students with “much more transparency” before they enroll. Further, the settlement also provides for continued tracking of students and career placement “to strengthen the school” and its educational mission as it moves forward.

Here’s the skinny—the settlement covers students enrolled at the school from July 2004 through February 2013. Students who qualify for claims will receive settlement notices by mail. Any money left unclaimed from the remaining funds in the escrow account after one year will be donated to nonprofit organizations dedicated to assisting the economically disadvantaged.

Ok folks, have a good one—see you at the bar!

Week Adjourned: 11.26.11

A wrap up of the week’s leading class action lawsuits and settlements – November 26, 2011

Top Class Actions

Do you know who’s got your personal information? An unfair business practices class action lawsuit has been filed in the Southern District Court of Florida against Best Buy Corporation for violating the Drivers’ Privacy Protection Act or “DPPA”, a federal statute that protects the privacy of personal information assembled by State Department of Motor Vehicles (DMVs).

The lawsuit alleges Best Buy has established a business practice of taking, storing, using and/or sharing customers’ personal or highly restricted personal information, without consent, when customers make a normal return of Best Buy merchandise. Their receipt indicates that Best Buy “tracks exchanges and returns … and some of the information from your ID may be stored in a secure, encrypted database of customer activity that Best Buy and its affiliates use to track exchanges and returns.”

The DPPA specifically prohibits Best Buy’s conduct and was instituted to protect consumers from abuses such as identify theft and stalking, which often result when information is unsecured and improperly stored. The class action alleges that Best Buy’s retention of data accessed on a driver’s license is not “use in the normal course of business” as described by the DPPA.

Top Settlements

What’s that old adage—if it sounds too good to be true… Power Balance LLC, the company that made Power Balance bracelets, has reportedly settled a consumer fraud class action lawsuit this week for $57.4 million and filed for federal bankruptcy protection. The details and amount of the Power Balance settlement remain to be confirmed, although it’s all over the Internet.

The company was sued over allegations of misleading advertising, advertising that allegedly claimed the hologram-embedded rubber bracelets enabled the wearers to “achieve their best,” a statement that begs the question—best what? Best outlandish claim? Possibly. Although the company claims there’s science to back up the statement. I have one word—and it’s “placebo.”

About time: Merck Vioxx settlement. There’s not much that’s funny about this. Merck, Sharp & Dohme has agreed to pay $950 million to resolve criminal charges and civil claims related to its promotion and marketing of the painkiller Vioxx (rofecoxib), the Justice Department announced. The FDA approved Vioxx for three indications in May 1999, but did not approve its use against rheumatoid arthritis until April 2002. In the interim, for nearly three years, Merck promoted Vioxx for rheumatoid arthritis, conduct for which it was admonished in an FDA warning letter issued in September 2001.

Merck is also entering into a civil settlement agreement under which it will pay $628,364,000 to resolve additional allegations regarding off-label marketing of Vioxx and false statements about the drug’s cardiovascular safety. Of the total civil settlement, $426,389,000 will be recovered by the United States, and the remaining share of $201,975,000 will be distributed to the participating Medicaid states. The settlement and plea conclude a long-running investigation of Merck’s promotion of Vioxx, which was withdrawn from the marketplace in September 2004.

The parallel civil settlement covers a broader range of allegedly illegal conduct by Merck. The settlement resolves allegations that Merck representatives made inaccurate, unsupported, or misleading statements about Vioxx’s cardiovascular safety in order to increase sales of the drug, resulting in payments by the federal government. It also resolves allegations that Merck made false statements to state Medicaid agencies about the cardiovascular safety of Vioxx, and that those agencies relied on Merck’s false claims in making payment decisions about the drug. Finally, like the criminal plea, the civil settlement also recovers damages for allegedly false claims caused by Merck’s unlawful promotion of Vioxx for rheumatoid arthritis.

Ok—That’s the week that was. Hope everyone had a wonderful Thanksgiving!